- Home
- URGN vs CSIQ Comparison
URGN vs CSIQ Comparison
Compare URGN & CSIQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- CSIQ
- Stock Information
- Founded
- URGN 2004
- CSIQ 2001
- Country
- URGN United States
- CSIQ Canada
- Employees
- URGN N/A
- CSIQ N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- CSIQ Semiconductors
- Sector
- URGN Health Care
- CSIQ Technology
- Exchange
- URGN Nasdaq
- CSIQ Nasdaq
- Market Cap
- URGN 904.0M
- CSIQ 746.1M
- IPO Year
- URGN 2017
- CSIQ 2006
- Fundamental
- Price
- URGN $18.79
- CSIQ $10.89
- Analyst Decision
- URGN Strong Buy
- CSIQ Hold
- Analyst Count
- URGN 8
- CSIQ 6
- Target Price
- URGN $28.50
- CSIQ $11.53
- AVG Volume (30 Days)
- URGN 1.1M
- CSIQ 2.1M
- Earning Date
- URGN 11-05-2025
- CSIQ 08-21-2025
- Dividend Yield
- URGN N/A
- CSIQ N/A
- EPS Growth
- URGN N/A
- CSIQ N/A
- EPS
- URGN N/A
- CSIQ N/A
- Revenue
- URGN $94,238,000.00
- CSIQ $5,919,361,000.00
- Revenue This Year
- URGN $39.63
- CSIQ $7.77
- Revenue Next Year
- URGN $111.49
- CSIQ $22.71
- P/E Ratio
- URGN N/A
- CSIQ N/A
- Revenue Growth
- URGN 10.85
- CSIQ N/A
- 52 Week Low
- URGN $3.42
- CSIQ $6.57
- 52 Week High
- URGN $21.71
- CSIQ $19.55
- Technical
- Relative Strength Index (RSI)
- URGN 48.50
- CSIQ 48.33
- Support Level
- URGN $18.45
- CSIQ $10.56
- Resistance Level
- URGN $21.71
- CSIQ $11.25
- Average True Range (ATR)
- URGN 1.18
- CSIQ 0.65
- MACD
- URGN -0.18
- CSIQ 0.08
- Stochastic Oscillator
- URGN 17.51
- CSIQ 61.67
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About CSIQ Canadian Solar Inc. (ON)
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.